Kornimate/medical-research-clean huggingface dataset:
a study of rpl554 drug administered by metered dose inhaler to treat chronic obstructive pulmonary disease

Conditions: COPD

Summary: the purpose of this study is to investigate 5 doses of rpl554 and placebo, administered by pressurized metered dose inhaler (pmdi), in patients with moderate to severe chronic obstructive pulmonary disease (copd).

the study will consist of two parts. part a is a parallel group, placebo-controlled single dose study to ascertain the pharmacokinetics (pk) profile, safety and bronchodilator effect of a single dose of rpl554 administered via pmdi. five of the 6 treatment arms will be double-blind and one will be single-blind (due to the different number of capsules administered). part b is a 7-day placebo-controlled, complete block cross-over, repeat dose study to assess the bronchodilator effect of repeat doses of rpl554 delivered via pmdi.

Eligibility criteria:
inclusion criteria: * male and female patients with moderate to severe copd, with a post bronchodilator fev1 of 40 to 80% of predicted and fev1/fvc ratio of ≤0.70. * they must have a baseline increase in fev1 of \>150 ml following four puffs of salbutamol. * they must have at least a 10 pack-year smoking history, and may be either a current or former smoker. exclusion criteria: * patients must be clinically stable without recent copd exacerbations or hospitalisations. * they must not have uncontrolled disease or chronic heart failure.

Keywords: copd adults phase ii rpl554 ensifentrine
bipolar surgical release in congenital muscular torticollis

Conditions: Congenital Muscular Torticollis

Summary: the congenital muscular torticollis is common disease in children.the indication for surgery is the children have persist deformity after 1 year old.many surgical treatment had proposed such as unipolar release and bipolar release.by author experience the bipolar release had better results from complete cut the muscle both origin and insertion.this study wants to study the results of treatment in term of recurrence of the deformity.

the study perform in children with congenital muscular torticollis

Eligibility criteria:
inclusion criteria: * 1. all children age ranged from 5-15 years old who received the surgical treatment by bipolar release in the hospital. exclusion criteria: * 1. no history of surgery at the neck 2. no history of congenital anomalies and syndrome that effect the neck
a study of apl-9 in adults with mild to moderate ards due to covid-19

Conditions: COVID; Covid-19; Coronavirus; Coronavirus Infection; Severe Acute Respiratory Syndrome; Severe Acute Respiratory Syndrome Coronavirus 2; Sars-CoV2; Ards; Acute Respiratory Distress Syndrome

Summary: the purpose of this study is to evaluate the safety and effectiveness of apl-9 in adults with mild to moderate ards (acute respiratory distress syndrome) caused by covid-19 who are hospitalized and require supplemental oxygen therapy with or without mechanical ventilation. it is thought that covid-19 activates the complement system, part of the immune system that responds to infection or tissue damage, and increases inflammation in the lungs. apl-9 has been designed to inhibit or block activation of part of the complement pathway, and potentially reduce inflammation in the lungs. part 1 of the study is open-label to evaluate safety; all participants will receive apl-9 plus standard of care. part 2 of the study is double-blind, randomized; participants will receive either apl-9 or the vehicle-control plus standard of care.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age at time of informed consent * diagnosis of active sars cov 2 infection using viral rna or viral antigen within 7 days of screening * respiratory failure requiring oxygen supplementation or either invasive or noninvasive mechanical ventilation with pao2/fio2 ratio \>100 mm hg. respiratory failure cannot be fully explained by cardiac failure or fluid overload. exclusion criteria: * treatment with immune checkpoint inhibitors, or other immunomodulators within 3 months prior to study enrollment (however, treatment with convalescent plasma, steroids, il-6 inhibitors, and antiviral agents is not excluded) * active bacterial, fungal, or parasitic infection * history of neuromuscular degenerative disease (eg, amyotrophic lateral sclerosis, duchenne muscular dystrophy, or multiple sclerosis) * current participation in an interventional clincial trial * subjects who have, at screening, been on mechanical ventilation for \>7 days have evidence of kidney and liver failure at screening * have a hereditary complement deficiency * pregnancy or breastfeeding
magnesium as an adjuvant agent for postoperative pain

Conditions: Pain, Postoperative

Summary: participants are being asked to participate in this research study because they have elected to undergo periacetabular osteotomy (pao). this research study is looking at if using iv magnesium during surgery can help to reduce pain after surgery.


Eligibility criteria:
inclusion criteria: * patients undergoing periacetabular osteotomy with or without adjuvant hip arthroscopy exclusion criteria: * illiterate or non-english speaking patients * patients with 2nd or 3rd degree av block * patients with severe renal insufficiency * patients with heart failure * patients with bradycardia

Keywords: periacetabular osteotomy iv magnesium sulfate decreased opioid usage
treating verbal memory deficits following chemotherapy for breast cancer

Conditions: Breast Cancer Treatment; Cognitive Deficits

Summary: the primary purpose of this study is to test the effects of a targeted, computerized cognitive training program on verbal memory in older women who have undergone chemotherapy treatment for early-stage breast cancer. as measured by neuropsychological assessment, this treatment will result in improved verbal memory. secondarily, processing speed and naming abilities are expected to improve. enhanced self-perception of cognitive ability is also expected.


Eligibility criteria:
inclusion criteria: * women ages 65-90 * chemotherapy treatment for early-stage (i, iia, iib, iiia) breast cancer * post-menopausal * high school education or greater * geographically available for followup assessment * native english speaker * normal or corrected to near-normal hearing and vision exclusion criteria: * psychiatric history including past or current psychotic spectrum disorders (schizophrenia, bipolar disorder, major depressive disorder, dementia, schizoaffective disorder) * brain injury (e.g., stroke, heart attack, aneurysm, tumor, concussion, head trauma) * brain disease * history of brain irradiation or surgery * current or past disease/disorder of the central nervous system or medical condition affecting cognitive functioning (e.g., chronic migraine, epilepsy or history of seizures, encephalitis, meningitis, multiple sclerosis, thyroid condition, parkinson's, alzheimer's, huntington's disease) * active diagnosis of autoimmune or inflammatory disorder (e.g., systemic lupus erythematosus, rheumatoid arthritis, vasculitis, insulin-dependent diabetes, crohn's disease, uncontrolled allergic reaction or asthma) * history of other cancer, except for basal cell carcinoma * development of a second primary malignancy during the study * drug or alcohol abuse (i.e., more than 7 drinks per week) * chronic use of oral steroid medication * former (prior to early-stage breast cancer) intrathecal therapy, radiation therapy, chemotherapy, or any neoadjuvant chemotherapy * acquired or developmental speech, language, or learning disorders (e.g., aphasia, dyslexia, dysgraphia, auditory processing disorder, autism, developmental delay) * hormone replacement therapy, excluding vaginal estrogen

Keywords: breast cancer chemotherapy verbal memory processing speed
humeral resurfacing hemiarthroplasty

Conditions: Advanced Glenohumeral Arthritis

Summary: the primary objective of this study is to examine quality of life outcomes in patients who have undergone a humeral surface replacement hemiarthroplasty.

resurfacing arthroplasty is gaining popularity for the reconstruction of advanced shoulder arthritis. new generation re-surfacing prostheses are engineered to anatomically restore a smooth articulating surface to the humeral head, while preserving bone stock, and potentially minimizing the risk for diaphyseal fracture. the results for shoulder resurfacing prostheses have largely been reported in retrospective reviews and have been very favorable. the purpose of this multi-centered, prospective study will be to determine the extent to which patient self-assessed outcomes (american shoulder and elbow society (ases) score) following humeral resurfacing improve compared to pre-operative ases scores.

Eligibility criteria:
pre-operative inclusion criteria: * failed standard non-surgical management (analgesics, nsaids, physiotherapy, activity modification) * persistent pain and disability for at least 6 months * imaging demonstrates advanced humeral head cartilage loss pre-operative exclusion criteria: * active or systemic joint infection * significant muscle paralysis of shoulder girdle * charcot's arthropathy * major medical illness (life expectancy \<2years) * unable to speak and read english/french * psychiatric illness that precludes informed consent * unwilling/unable to remain in study for one year intra-operative inclusion criteria: advanced humeral head cartilage loss and one of: * minimal/no glenoid cartilage loss * complete glenoid cartilage loss and no bony erosion * complete glenoid cartilage loss and concentric bony erosion with no humeral anterior/posterior subluxation intra-operative exclusion criteria: * eccentric glenoid erosion with biconcavity of glenoid and subluxation of humeral head * inability of humeral head to support the cap surface replacement
cavernous tissue preservation during penile prosthesis implantation

Conditions: Erectile Dysfunction

Summary: spontaneous penile tumescence after penile prosthesis implantation has been previously reported as sporadically occurring during implant surgery. this study aims at systematically preserving residual erectile function, by the preservation of the patients' spontaneous penile tumescence by systematically sparing cavernous tissue during penile prosthesis implantation.

patients undergoing the cavernous tissue sparing penile implant procedure will be injected intraoperatively with 40µg alprostadil, a prostaglandin e1 agonist intracorporal injection (ici). the procedure will begin as soon as maximal tumescence is attained. in the cavernous sparing group, corporal dilation will be done solely with a size 8 dilator. the insertion of the dilator will be carefully inserted in what we call the path of least resistance. to determine the path of least resistance, the corporotomy is spread apart by pulling on previously set stay sutures. the path of least resistance is the plane with maximum outflow of blood from the intraoperatively pharmaceutically dilated and blood filled corpora cavernosa. this plane can also be anticipated with a preoperative penile duplex.

Eligibility criteria:
inclusion criteria: * erectile dysfunction not amenable to treatment by approved medical therapy exclusion criteria: * erectile dysfunction amenable to treatment by approved medical therapy

Keywords: erectile dysfunction penile tumescence cavernous tissue
the effect of continuous midwifery care at birth on labor pain, comfort and satisfaction

Conditions: Labor Pain

Summary: introduction: birth is a period in which biological, physical, emotional and social changes are experienced. supportive care provided by the midwife ensures the adaptation of the woman to labor and improves her ability to cope with labor. supportive care has positive effects on labor and maternal and infant health. purpose: this project aimed to determine the birth pain, comfort and satisfaction levels by considering the continuous midwifery care at birth with a holistic approach. method: the universe of this study, which will be conducted in randomized controlled experimental type, will consist of pregnant women who applied to adana city training and research hospital, gynecology and obstetrics clinic, delivery room. the number of samples was calculated by g\*power analysis, and it was aimed to carry out the research with 30 participants in the intervention group and 30 participants in the control group. single-blind randomized assignment and block randomization will be performed to avoid selection bias. data will be collected using face-to-face interview technique. the pre-test will be applied to pregnant women who apply to the delivery room in the latent phase. while the continuous midwifery care model will be applied to the intervention group, standard midwifery care will be applied to the control group. the final test will be done between 1-4 hours postpartum. the independent variable of the study is continuous midwifery care. the dependent variable is the introductory characteristics of women, labor pain, comfort and satisfaction levels. the data will be analyzed with appropriate analysis methods after performing normality tests.

during childbirth, women need someone's support. providing continuous care to women with a supportive and holistic approach by midwives who care for women is seen as a potential that can improve labor pain management, birth comfort and satisfaction. the aim of this research is to determine the effect of continuous midwifery care at birth on labor pain, comfort and satisfaction levels. for this purpose, the objectives are: * to apply the continuous midwifery care model, * to increase women's normal birth comfort and satisfaction, * to create social awareness that midwives play a key role in normal birth, * reducing preventable maternal and infant and infant deaths due to care deficiencies, * to reduce cesarean rates.

Eligibility criteria:
inclusion criteria: * volunteering to participate * knowing turkish and being literate, * don't be in the latent phase. exclusion criteria: * high risk pregnancy * multiple pregnancy * breech presentation * induction of labor * emergency cesarean section indication

Keywords: continuous midwifery care supportive care labor pain comfort,
efficacy and safety of adjuvant pemetrexed plus cisplatin for adenocarcinoma of lung

Conditions: Adenocarcinoma; Lung Neoplasm

Summary: two-year disease free survival rate of stage ib\~iiia adenocarcinoma after adjuvant chemotherapy with pemetrexed and cisplatin will be assessed. a total of 106 patients will be recruited for 12 months, and followed for two years, thus the duration of study will be 36 months.

primary endpoint : 2 year disease free survival secondary endpoints: overall survival, frequency and severity of adverse events

Eligibility criteria:
inclusion criteria: * adenocarcinoma of lung * postoperative pathologic stage ib\~iiia * complete surgical resection (r0 resection) n1-2: r0 resection with lobectomy and mediastinal lymph nodes dissection (mlnd) n0: r0 resection with lobectomy with or without mlnd * adjuvant treatment should start between 4 to 6 weeks after surgery * ecog performance status 0-1 * weight loss during last 3 months should be less than 10%. * normal hematologic, hepatic and renal function neutrophil count \> 1500 /microliter, platelet \> 100,000/microliter, hemoglobin \> 9 g/dl bilirubin \<=1.5 x upper limit normal, transaminase \< 2.5 x upper limit normal serum creatinine \<=1.5 mg/dl * women in child bearing age should consent using contraceptive measures, and must have negative pregnancy test. exclusion criteria: * other malignant neoplastic disease within 5 years. * neoadjuvant chemotherapy before surgery of lung cancer * patients who will be treated with postoperative radiation. * stage iiib or iv lung cancer * severe infection, or cardiorespiratory, hematologic illness * hiv positive cases * pregnancy or lactating women * autoimmune diseases or those who receiving immune suppressive treatment * symptomatic neuropathy \> ctcae grade 1 * those who consented other clinical trials within 3 months * other significant medical conditions contraindicated to clinical trial

Keywords: adenocarcinoma lung adjuvant chemotherapy pemetrexed cisplatin surgery
computer screen properties study

Conditions: Dry Eye Syndromes

Summary: the purpose of this study is to identify how various popular methods of changing computer screen settings affect dry eye symptoms (eye pain, grittiness, tearing, burning, etc.). specifically, this study will examine if there are differences in effects of blue light blocking (f.lux app or night shift) versus reducing screen brightness on the symptoms of dry eye.

after the initial survey, participants will be randomized by a randomization tool internal to redcap to be in one of three arms of intervention: no intervention, screen brightness reduction to 50%, and tone modulator application. instructions will be e-mailed to participants to explain the steps they must take depending on which treatment arm they are randomized to. adherence will be monitored and assessed at the time of post-intervention survey. if participants have issues with the software of complying, they will be able to contact the research team at any point.

Eligibility criteria:
inclusion criteria: * adult person (18+) with intact vision who uses computers exclusion criteria: * children (\<18 years) * adult person without intact vision * adult who does not use computer screens
therapeutic effect of vitamin c supplementation in patients with ovarian aging

Conditions: Premature Ovarian Insufficiency; Ovarian Reserve Function

Summary: the goal of this clinical trial is to learn if vitamin c works to improve ovarian reserve in women with ovarian aging. it will also learn about the safety of vitamin c. the main questions it aims to answer are: * does vitamin c supplementation improve the ovarian reserve prediction score? * what medical problems do participants have when taking vitamin c supplementation? researchers will compare vitamin c to a placebo (a look-alike substance that contains no drug) to see if drug vitamin c works to improve ovarian reserve in women with ovarian aging. participants will: * take vitamin c or a placebo every day for 12 months * visit the clinic once every 4 weeks for follow-up and drug distribution. * return the vitamin c box at each visit. * report any adverse effects of treatment to the doctor. * fill out a questionnaire at each visit. * after 6 months and 12 months of intervention, take blood test and ultrasonic examination.


Eligibility criteria:
inclusion criteria: * regularity of menstruation changed for less than one year. * 10u/l≤ fsh\<25 u/l in two tests more than 4weeks aprt. * amh \< 1.1 ng/ml. * bilateral ovarian afc \<7. * signed informed consent and can participate in regular follow-ups. exclusion criteria: * ovarian aging caused by tuner (x deletion) syndrome or gene mutation. * ovarian aging caused by ovarian surgery or chemotherapy. * patients with severe endocrine system diseases (diabetes, thyroid disease), digestive system diseases (affecting vc absorption), cardiovascular system diseases, renal insufficiency (abnormal urine, imaging diagnosis, blood, pathological analysis confirms that kidney damage does exist, or glomerular filtration rate gfr \<60ml/min), nervous system diseases such as dementia and epilepsy; patients with infectious diseases such as hiv, hepatitis, tuberculosis; patients with severe autoimmune diseases. * continuous alcohol or drug abuse (to avoid adverse reactions caused by drinking). * allergic to vitamin c or any component of the preparation. * patients who have already started large-dose (greater than 500mg/day) vitamin c supplementation. * unwilling to or stop taking supplements not provided by this project. * those who have participated in other ovarian aging clinical intervention projects.
evaluation of the accuracy and precision of flash glucose monitoring sensors in different sites

Conditions: Diabetes Mellitus, Type 1

Summary: on the first of july 2016, reimbursement for the freestyle libre flash glucose monitoring (fgm) was introduced by the belgian healthcare authority by means of a new diabetes convention. making this the only way to receive the device in belgium. since then, many type 1 diabetes (t1d) patients switched to fgm. but some patients found the sensor on the upper arm too visible. abbott does not recommend to place the sensor on a different place of the body than the back of the upper arm, because no tests were done yet (besides on the upper arm) to make an accuracy claim. with this study, we want to evaluate the accuracy and the precision of the freestyle libre fgm by using three fgm sensors simultaneously on different places of the body and perform regular self-monitoring of blood glucose (smbg) tests.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of t1d for more than 6 months * adult patients ≥ 18 years * signed informed consent form exclusion criteria: * pregnancy * patients with severe cognitive dysfunction or other disease which makes fgm use difficult. * history of allergic reaction to any of the fgms materials or adhesives when in contact with the skin. * history of allergic reaction to chlorhexidine or alcohol anti-septic solution. * abnormal skin at the anticipated glucose sensor insertion sites (excessive hair, burn, inflammation, infection, rash, and/or tattoo). * presence of concomitant pathology that might cause edema at the insertion sites (such as heart failure, liver failure, kidney failure defined as egfr \< 45 ml/min).

Keywords: flash glucose monitoring accuracy precision
randomized controlled trial of acupuncture to treat bell's palsy according to different stages

Conditions: Bell's Palsy

Summary: the purpose of this trial will certify the efficacy of using staging acupuncture and moxibustion to treat bell's palsy

the result of this trial (available in 2009) aims to testify the efficacy of using staging acupuncture and moxibustion to treat bell's palsy, and to approach a best acupuncture treatment among these five different methods for treating bell's palsy

Eligibility criteria:
inclusion criteria: * patients who meet the diagnosis, stages, location criteria * the first time to onset the disease * between 1 and 70 days with the onset time of facial palsy * on one side of the face paralysis * between 15 and 70 years old with the onset age of facial palsy * willing to finish the whole observation period * with written consent form signed by themselves. exclusion criteria: * facial palsy caused by other disease, such as infectivity multiple radiculitis, tumor which offend temporal bone, cerebral trauma * facial palsy combine diabetes, the severe disease of heart vessel, cerebral vessel, liver, kidney, lung, and psychosis * patient with hunt's syndrome * patient with facial spasm * pregnant women or women in lactation * patients are participating other clinical research

Keywords: peripheral facial paralysis acupuncture rct